A Double-Blind, Randomized Comparison Study between Zytux™ vs MabThera® in Treatment of CLL with FCR Regimen: Non-Inferiority Clinical Trial.

International journal of hematology-oncology and stem cell research（2018）

引用 30|浏览16

暂无评分

摘要

Results showed non-inferiority of Zytux™ in terms of efficacy and adverse events as a biosimilar version of MabThera.

查看译文

关键词

Chronic lymphocytic leukemia,Clinical trial,Mabthera®,Rituximab,Zytux™

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要